Financial Performance - Revenue for the first nine months of 2024 was CNY 107.24 million, a decrease of 23.98% compared to CNY 141.07 million in the same period of 2023[5]. - The net profit attributable to shareholders for the first nine months of 2024 was a loss of CNY 3.79 million, a decline of 119.76% from a profit of CNY 19.16 million in the previous year[5]. - In Q3 2024, revenue increased by 9.09% to CNY 43.93 million compared to CNY 40.27 million in Q3 2023[6]. - The net profit attributable to shareholders in Q3 2024 was CNY 0.79 million, down 80.56% from CNY 4.04 million in Q3 2023[6]. - Total operating revenue for the first nine months of 2024 is 107,242,146.61 CNY, a decrease of 24% compared to 141,067,004.29 CNY in the same period of 2023[28]. - Net profit for the first nine months of 2024 is -5,456,105.74 CNY, compared to a net profit of 19,790,768.29 CNY in the same period of 2023, indicating a significant decline[29]. - The total comprehensive income for the first nine months of 2024 is -5,515,920.04 CNY, compared to 20,016,655.91 CNY in the same period of 2023[29]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 424.93 million, reflecting a 1.33% increase from CNY 419.35 million at the end of 2023[4]. - The company’s total liabilities to total assets ratio increased to 17.79% in 2024 from 13.12% in 2023[4]. - Current liabilities rose to CNY 67.56 billion, compared to CNY 45.92 billion in the previous period, marking an increase of about 47%[23]. - The total liabilities increased significantly to CNY 75.61 billion, up from CNY 55.02 billion, reflecting a growth of approximately 37.5%[23]. - Shareholders' equity decreased to CNY 349.32 billion from CNY 364.33 billion, indicating a decline of about 4.1%[24]. - The total liabilities and shareholders' equity amounted to CNY 429.58 billion, up from CNY 413.30 billion, reflecting an increase of about 3.9%[27]. Cash Flow - The company reported a significant decrease in cash flow from operating activities, with a net outflow of CNY 25.53 million, a decline of 189.99% compared to a net inflow of CNY 28.38 million in the same period last year[5][8]. - Cash inflow from operating activities was CNY 120,505,064.72, down from CNY 169,813,382.67 year-on-year[33]. - Net cash flow from operating activities was negative at CNY -25,534,455.47, compared to a positive CNY 28,376,336.35 in the same period last year[33]. - Cash inflow from investment activities totaled CNY 165,976,578.21, a decrease from CNY 276,917,883.53 year-on-year[34]. - Net cash flow from investment activities was CNY -1,744,056.29, compared to CNY 5,901,786.62 in the previous year[34]. - Cash inflow from financing activities was CNY 20,150,000.00, significantly higher than CNY 3,380,000.00 in the previous period[34]. - The ending cash and cash equivalents balance was CNY 19,849,279.85, down from CNY 48,825,825.95 in the previous year[34]. Shareholder Information - The total number of unrestricted shares at the end of the period was 55,295,053, accounting for 56.60% of total shares[10]. - The total number of restricted shares at the end of the period was 42,391,590, accounting for 43.40% of total shares[10]. - The total share capital at the end of the period was 97,686,643 shares[10]. - The number of shareholders holding more than 5% of shares totaled 71,144,474, representing 72.83% of total shares[11]. - The company granted 675,000 restricted shares and 805,000 stock options to 58 incentive objects, including directors and core employees[15]. Operational Expenses - Total operating costs decreased to 114,942,454.21 CNY, down from 122,022,382.32 CNY, reflecting a cost reduction strategy[28]. - Research and development expenses for the first nine months of 2024 are 16,140,001.67 CNY, slightly down from 17,170,364.95 CNY in the same period of 2023[28]. - Sales expenses increased to 30,646,276.41 CNY from 21,637,310.76 CNY, indicating higher marketing efforts[28]. Equity Incentives - The company adjusted the exercise price of stock options from ¥22.50 to ¥22.30 and the grant price of restricted stock from ¥11.30 to ¥11.10 due to equity distribution, affecting 985,000 options[16]. - As of September 30, 2024, the company granted a total of 675,000 restricted shares and 945,000 stock options under the 2022 equity incentive plan, with 181,800 shares released from restrictions and 447,700 shares and 1,205,565 options canceled[20]. - The company plans to cancel 99,318,200 stock options and 385,000 restricted shares due to unmet performance conditions and employee departures[19]. - The total amount of restricted shares granted under the 2022 equity incentive plan was adjusted to 1,484,649 options and 97,648 reserved options[18].
锦好医疗(872925) - 2024 Q3 - 季度财报